journal article·2010-05

Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU

Laure Brévignon-Dodin

Publisher page

Abstract

The EU Regulation on Advanced Therapy Medicinal Products (ATMP) bridges a regulatory gap and is expected to act as an enabler for the regenerative medicine sector in the EU by setting a centralised and harmonised regulatory framework for tissue-engineered products. Some of its key features are a workable and comprehensive scope, a new committee allowing for a pooling of expertise and tailored yet flexible requirements meant to keep pace with technology development. However, while providing a much needed regulatory framework, the new regulation still has potential shortfalls with regard to facilitating the research and commercialisation of tissue-engineered products in the future.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Biomedical Ethics and Regulation · Pluripotent Stem Cells Research · Tissue Engineering and Regenerative Medicine

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute for Manufacturing, Department of Engineering, University of Cambridge, Cambridge, UK

References

Reference metadata was not supplied for this record.